83-2271-50　［受注停止］KRIBIOLISA Lenalidomide （REVLIMID） ELISA 1 x 96 wells　KOD1010

特徴

• Description：Enzyme Immunoassay for the quantitative determination of
• Lenalidomide （REVLIMID） in serum, plasma and cell culture
• supernatant
• Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple
• myeloma （MM） and myelodysplastic syndromes （MDS）.
• There are multiple mechanisms of action, and they can
• be simplified by organizing them as mechanisms of action in vitro and in vivo.
• In vitro, lenalidomide has three
• main activities： direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation.
• In vivo, lenalidomide
• induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-
• angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
• Lenalidomide has a broad
• range of activities that can be exploited to treat many hematologic and solid cancers.
• On a molecular level,
• lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon and target this enzyme to degrade
• the Ikaros transcription factors IKZF1 and IKZF3.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the quantitative competitive enzyme immunoassay technique.
• The microtiter wells are
• coated with Lenalidomide antigen.
• Lenalidomide present in the sample competes with antigen coated on the
• microtiter plate for the antibody.
• After incubation and washing, Biotin Lenalidomide： HRP Conjugate is added
• and incubated.
• Post incubation TMB substrate is added which develops blue color during incubation period and
• the reaction is stopped after the addition of stop solution with development of yellow color.
• The intensity of the
• color generated is inversely proportional to the amount of lenalidomide present in the sample.